1. 130P COM701 ± nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor. (December 2022) Authors: Sullivan, R.J.; Sharma, M.R.; Vaena, D.; Hamilton, E.; Izar, B.; Rasco, D.; Gainor, J.; D. Shepard, ; Papadopoulos, K.; Dumbrava, E.E.; Adewoye, H.H.; Ferre, P.J.; Ophir, E.; Patel, M.; Patnaik, A.; Chmielowski, B. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 158P Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant OVCA. (December 2022) Authors: Moroney, J.; Yeku, O.; Fleming, G.; Emens, L.A.; Vaena, D.; Dumbrava, E.E.; Rasco, D.; Sharma, M.R.; Papadopoulos, K.; Patnaik, A.; Sullivan, R.J.; Adewoye, H.H.; Ophir, E.; Cojocaru, G.; Ferre, P.J.; Izar, B.; Gaillard, S. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 361 Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1-3 and 15-17 every 28 days to patients with advanced malignant solid tumors. (September 2015) Authors: Hidalgo, M.; Boni, V.; Tolcher, A.; Smith, L.; Cubillo, A.; Rasco, D.; Calvo, E.; Amaya, A.; Ordoñez, E.; Patnaik, A.; Cerda, S.; Coronado, C.; Fudio, S.; Miguel-Lillo, B.; Prados, R.; Ortega, O.; Soto-Matos, A.; Papadopoulos, K.P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Comparative analysis of wear behavior of garnet and fly ash reinforced Al7075 hybrid composite. Issue 1 (15th January 2019) Authors: Mishra, S.; Patnaik, A.; Kumar, S.R. Journal: Materialwissenschaft und Werkstofftechnik Issue: Volume 50:Issue 1(2019:Jan.) Page Start: 86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Comparison of ballistic performances of Al2O3 and AlN ceramics. (December 2016) Authors: Pawar, M.J.; Patnaik, A.; Biswas, S.K.; Pandel, U.; Bhat, I.K.; Chatterjee, S.; Mukhopadhyay, A.K.; Banerjee, R.; Babu, B.P. Journal: International journal of impact engineering Issue: Volume 98(2016:Dec.) Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Comparison of ballistic performances of Al2O3 and AlN ceramics. (December 2016) Authors: Pawar, M.J.; Patnaik, A.; Biswas, S.K.; Pandel, U.; Bhat, I.K.; Chatterjee, S.; Mukhopadhyay, A.K.; Banerjee, R.; Babu, B.P. Journal: International journal of impact engineering Issue: Volume 98(2016:Dec.) Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Development and characterization of HER2+ T-DM1-resistant breast cancer PDX models. (December 2016) Authors: Wick, M.; Moriarty, A.; Quinn, M.; Vaught, T.; Rundle, M.; Tolcher, A.; Rasco, D.; Patnaik, A.; Papadopoulos, K. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Establishment and characterization of a hormone dependent, PSA/PSMA positive prostate PDX model. (December 2016) Authors: Wick, M.; Quinn, M.; Mangold, A.; Gamez, L.; Diaz, A.; Vaught, T.; Reyna, J.; Tolcher, A.; Rasco, D.; Patnaik, A.; Papadopoulos, K. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Establishment and characterization of a panel of BRAFV600E colorectal XPDX models from patients with acquired resistance to targeted therapies. (October 2022) Authors: Moriarty, A.; Flores, J.; Peskin, A.; Lynch, M.; Papadopoulos, K.; Lakhani, N.; Sharma, M.; Drengler, R.; Szender, J.; Rasco, D.; Patnaik, A.; Bucheit, A.; Wick, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Establishment and characterization of an EGFR-mutant NSCLC XPDX model representing first-line osimertinib resistance through an acquired TRIM24-BRAF fusion. (October 2022) Authors: Moriarty, A.; Flores, J.; Stackpole, A.; Ulmer, S.; Papadopoulos, K.; Patnaik, A.; Rasco, D.; Calvo, E.; Moreno, V.; Wick, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗